Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a renowned American multinational pharmaceutical company headquartered in Rahway, New Jersey. Originally the American arm of Germany's Merck Group founded in 1668, Merck has established itself as a global leader in pharmaceuticals and vaccines.
Merck's core business is the development and manufacturing of medications and vaccines spanning several therapeutic areas such as cardiometabolic diseases, cancer, and infections. The company's immuno-oncology platform, particularly strong in cancer treatment, is a significant revenue driver. The firm’s oncology portfolio includes groundbreaking immunotherapies like KEYTRUDA, designed to treat melanoma and other cancers. KEYTRUDA, in combination with other therapies, has shown promising results in reducing cancer recurrence and improving survival rates.
Merck also boasts a robust vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their commitment to public health extends to Merck for Mothers, an initiative aimed at improving maternal health globally. In 2024, Merck surpassed its goal early by reaching over 30 million women with programs promoting safe, high-quality maternal care.
The company's animal health division is another sector of its diverse operations, providing solutions to improve animal health and productivity.
From a geographical perspective, nearly half of Merck's sales are generated in the United States. Financially, Merck maintains a solid position with ongoing investments in research and development to fuel innovation. The company is actively engaged in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.
Merck’s mission is rooted in scientific excellence and an unwavering commitment to improving lives. The company continues to invest in leading-edge research, with over 2,250 ongoing clinical trials, including more than 1,600 trials evaluating combination regimens. This dedication underpins Merck's strategy to address complex health challenges and advance global health.
Seagen, Astellas Pharma, and Merck announced the FDA's acceptance of supplemental Biologics License Applications for their combination therapy of PADCEV and KEYTRUDA, targeting locally advanced or metastatic urothelial cancer patients ineligible for cisplatin-based chemotherapy. The FDA granted the applications Priority Review, setting a PDUFA date of April 21, 2023. The combination therapy, previously designated as Breakthrough Therapy, is supported by clinical trial data. Continued research includes a phase 3 study to assess the treatment's efficacy and facilitate potential accelerated approval.
Astellas Pharma, Seagen, and Merck announced that the FDA has accepted their applications for Priority Review of PADCEV® and KEYTRUDA® in combination for treating locally advanced or metastatic urothelial cancer. This therapy aims to provide a new treatment option for patients who cannot receive cisplatin-based chemotherapy. The FDA set a PDUFA date of April 21, 2023, for potential accelerated approval. Supported by data from the EV-103 trial, the combination has shown promise, with additional studies ongoing to further evaluate its effectiveness.
AstraZeneca and Merck (NYSE: MRK) announced an extension to the FDA's Prescription Drug User Fee Act (PDUFA) date by three months for the supplemental new drug application (sNDA) regarding LYNPARZA in combination with abiraterone and prednisone for treating metastatic castration-resistant prostate cancer (mCRPC). The extension aims to allow further review of the application, which is supported by the Phase 3 PROpel trial data. LYNPARZA is already approved for certain indications in the U.S. and EU, with ongoing regulatory reviews in additional countries.
Moderna and Merck announced positive results from the Phase 2b KEYNOTE-942 trial of mRNA-4157/V940 combined with KEYTRUDA in stage III/IV melanoma patients. The study showed a 44% reduction in the risk of disease recurrence or death compared to KEYTRUDA alone. This marks the first efficacy demonstration of an mRNA cancer treatment in a randomized trial. The companies plan to initiate a Phase 3 study and expand to other tumor types in 2023. Adverse events associated with mRNA-4157/V940 were consistent with previous studies, indicating manageable safety.
Merck (NYSE: MRK) has initiated a cash tender offer for all outstanding shares of Imago BioSciences (NASDAQ: IMGO) at $36 per share. This follows a definitive agreement announced on November 21, 2022, to acquire Imago. The tender offer is set to expire on January 10, 2023. Upon successful completion, Imago will merge into a Merck subsidiary and become a wholly-owned entity. The tender offer is subject to conditions, including the tender of a majority of Imago's shares and necessary regulatory approvals. Closing is expected in Q1 2023.
Merck (NYSE: MRK) announced the presentation of new data on investigational drugs, including favezelimab, zilovertamab vedotin, and nemtabrutinib, at the 64th American Society of Hematology (ASH) Annual Meeting from Dec. 10-13, 2022, in New Orleans and virtually. Key findings will involve nearly 40 abstracts showcasing advancements in blood cancer treatments, including new insights on KEYTRUDA (pembrolizumab). Dr. Gregory Lubiniecki emphasized Merck's commitment to enhancing the treatment landscape for blood cancer patients and the importance of their growing pipeline of therapies.
Merck (NYSE: MRK) announced a quarterly dividend of
Merck (NYSE: MRK) announced positive topline results from the pivotal Phase 3 KEYNOTE-859 trial, where KEYTRUDA® (pembrolizumab) combined with chemotherapy significantly improved overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) for patients with HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma. The independent Data Monitoring Committee confirmed these statistically significant findings. No new safety concerns were identified. Results will be presented at future medical meetings and submitted for regulatory review.
Merck's potential approval for LYNPARZA in combination with abiraterone for treating metastatic castration-resistant prostate cancer (mCRPC) has gained a positive opinion from the European Medicines Agency's CHMP. The Phase 3 PROpel trial results showed a 34% reduction in disease progression or death compared to placebo, with median radiographic progression-free survival of 24.8 months. While the safety profile aligns with prior studies, 14% of patients discontinued treatment due to side effects, including anemia and fatigue.
FAQ
What is the current stock price of Merck & Co (MRK)?
What is the market cap of Merck & Co (MRK)?
What are the main therapeutic areas Merck focuses on?
What is Merck for Mothers?
What are some of Merck’s key products in oncology?
How significant is Merck’s vaccine business?
Where is Merck headquartered?
What percentage of Merck’s sales comes from the United States?
What is Merck's approach to research and development?
What recent achievements has Merck announced?
Does Merck collaborate with other companies for research?
What is the historical origin of Merck & Co., Inc.?
